Seer
Provides the Proteograph platform for deep, unbiased proteomics research.
Something off on this page? Send us feedback.
Profile
Sells the Proteograph platform: engineered nanoparticles, automation instruments, consumables, and analytical software for research proteomics. Access comes through instrument and kit purchases or the Seer Technology Access Center. The business is organized around a single platform.
Built around the Proteograph platform, engineered nanoparticles, automation instruments, consumables, and analytical software support deep, unbiased proteomics research. The current suite includes the Proteograph ONE Assay and SP200 Automation Instrument, and is intended for research rather than diagnostic or clinical use. Its workflow is designed to make deep proteomics usable at scale.
Instrument and kit purchases sit alongside access through the Seer Technology Access Center. The products serve researchers seeking molecular insight into biology and disease, while teams span North America, the European Union, and the United Kingdom. The business is organized around a single platform rather than unrelated segments.
Company facts
Categories
Key statistics
Year to date +9.3% · Average volume (30d) 714.0K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| May 4, 2026 | Canaccord Genuity | Target | $4 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026Q2 FY26 | −$0.27 | −$0.31 | −14.8% | $3.6M | $3.1M | −12.6% | −0.93% |
| May 13, 2026Q1 FY26 | −$0.30 | −$0.30 | −1.7% | $3.6M | $2.8M | −22.4% | −1.13% |
| Feb 26, 2026Q4 FY25 | −$0.32 | −$0.29 | +9.4% | $4.6M | $4.2M | −8.7% | −17.31% |
| Nov 6, 2025Q3 FY25 | −$0.32 | −$0.32 | 0.0% | $4.6M | $4.1M | −10.4% | −3.24% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $3.9M | $4.0M | $4.1M | $2.7M | $3.1M | |
| Gross profit | $2.0M | $2.0M | $2.0M | $2.1M | $895.0K | $1.5M | |
| Operating income | −$20.7M | −$20.5M | −$19.3M | −$17.4M | −$17.3M | −$16.8M | |
| Net income | −$19.9M | −$19.4M | −$18.2M | −$16.0M | −$16.8M | −$16.9M | |
| Diluted EPS | −$0.34 | −$0.33 | −$0.32 | −$0.29 | −$0.30 | −$0.31 | |
| Gross margin | 48.3% | 50.7% | 49.3% | 50.5% | 33.1% | 48.5% | |
| Operating margin | -500.1% | -522.1% | -487.4% | -426.8% | -637.7% | -542.9% |
Fiscal years (4-quarter sums)FY21 $6.5M · FY22 $14.7M · FY23 $16.4M · FY24 $14.0M · FY25 $16.1M
Balance sheet, Jun 30, 2026Cash & short-term investments $152.9M · Total debt $22.4M · Total assets $256.6M · Shareholders' equity $225.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 54.98M · Float 40.14M · 73.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Omid Farokhzad | 6.92M | 12.00% | 13G | May 15, 2026 |
| SoftBank Group Corp. | 5.14M | 9.34% | 13F | May 15, 2026 |
| Schindel Yair Chaim | 4.92M | 8.35% | 13G | Jan 8, 2025 |
| Siren, L.L.C. | 2.46M | 4.47% | 13F | May 14, 2026 |
| Acadian Asset Management LLC | 2.07M | 3.77% | 13F | May 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | David R. Horn | officer: PRESIDENT & CFO | −7,309 | $2.03 |
| Jul 8, 2026 | Dipchand Nishar | director | −10,660 | $2.18 |
| May 20, 2026 | David R. Horn | officer: PRESIDENT & CFO | −7,303 | $1.69 |
| Feb 18, 2026 | Omid Farokhzad | director, officer: CEO AND CHAIR | −24,385 | $1.99 |
| Feb 18, 2026 | David R. Horn | officer: PRESIDENT & CFO | −7,743 | $1.99 |
Peers
- Thermo Fisher Scientific
Orbitrap and Astral workflows for discovery proteomics
- Bruker
timsTOF mass spectrometry and proteomics workflows
- Agilent Technologies
LC/MS, sample-prep, and automation workflows for proteomics
- Danaher
SCIEX mass-spectrometry and separation workflows for proteomics
- Bio-Techne
Protein-analysis reagents and instruments for proteomics research
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Seer | $1.97 | −1.01% | $108.9M | — | — | 7.9 | −23.4% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Bruker | $57.08 | +0.04% | $8.69B | — | 25.2 | 2.5 | +5.2% |
| Agilent Technologies | $153.84 | +0.02% | $43.45B | 30.3 | 23.8 | 5.9 | +8.1% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Bio-Techne | $72.36 | +0.01% | $11.33B | 62.4 | 34.9 | 9.3 | +1.3% |
| Median | 35.9 | 24.3 | 5.9 | +5.5% |